Huateng Pharma Develops CDK4/6 Inhibitors Against Breast Cancer
Breast cancer is one of the most common malignant tumors in women, and its incidence rate ranks first in female malignant tumors. Male breast cancer is relatively rare. With the improvement of medical treatment, breast cancer has become one of the solid tumors with the best curative effect.
The global breast cancer drug market will grow from US$31.50 billion in 2022 to US$33.96 billion in 2023, with a compound annual growth rate (CAGR) of 7.8%, of which HER2-targeted drugs and CDK4/6 inhibitors account for the most.
There are currently 5 CDK4/6 inhibitors on the market worldwide, including Palbociclib, Abemaciclib, Ribociclib, Trilaciclib and Dalpicilib. The total global market size of the remaining four models has continued to grow to nearly US$9 billion based on the latest financial report data. At present, many domestic pharmaceutical companies are also deploying CDK4/6 inhibitors.
Their main approved indications include combination therapy for first-line treatment of postmenopausal ER+/HER2- advanced breast cancer, combination therapy for HR+/HER2- postmenopausal advanced breast cancer that failed previous endocrine therapy, only Abemaciclib approved for HR+/HER2- early breast cancer indication.
Based on the excellent therapeutic effect and good safety of CDK4/6 inhibitor combined with endocrine therapy, it has become the standard regimen recommended by domestic and foreign guidelines for the first-line treatment of HR+/HER2- advanced breast cancer.
“In response to this trend, our management decides to introduce a new product line, providing Palbociclib and Ribociclib intermediates with high purity and the most reasonable price,” says the Marketing Chief of Huateng Pharma. ”Previously, we have already been a trust-wothy CDMO for pharmaceutical intermediates, offering custom synthesis and scale-up services for many years. We believe our relationship with our partners will be further strengthened after the launch of these popular pharmaceutical intermediates.”
As a leading pharmaceutical intermediates supplier in China, Huateng Pharma can provide Palbociclib intermediates and Ribociclib intermediates with high purity from lab to commercial scale. Also, we can provide CDMO services to meet your requirements, combining a high level of competencies, equipment and quality.
About Huateng Pharma
Huateng Pharma is a global provider in contract development and manufacturing for intermediates. With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility.
Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818